Development of new therapeutic drugs based on the pathophysiology of schizophrenia

DOI Web Site
  • Hashimoto Kenji
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health

Bibliographic Information

Other Title
  • 統合失調症の病態からみた新しい治療薬の開発
  • トウゴウ シッチョウショウ ノ ビョウタイ カラ ミタ アタラシイ チリョウヤク ノ カイハツ

Search this article

Description

Accumulating evidence suggests that the hypofunction via N-methyl-D-aspartate (NMDA) receptors plays a role in the pathophysiology of schizophrenia. Based on the NMDA receptor hypofunction hypothesis of schizophrenia, the novel therapeutic drugs for schizophrenia have been developing as follows : metabotropic glutamate receptor (mGluR2/3) agonists, D-serine plus D-amino acid oxidase (DAO) inhibitors, glycine transporter (GlyT-1) inhibitors. Furthermore, the second antibiotic drug minocycline is also one of the attractive therapeutic drugs for schizophrenia. Here the author would like to discuss the possibility of these therapeutic drugs for schizophrenia.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top